Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy WHWK?
Source: PRnewswire
- MUC16 Target Advantage: MUC16 is expressed at least two-fold higher in ovarian cancer compared to other emerging targets and is stably expressed in the most aggressive and common subtypes of endometrial cancer, indicating its potential as a clinically meaningful ADC target that could provide new treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing a Phase 1 clinical trial for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, which will provide critical clinical evidence for its application in cancer treatment.
- Technological Innovation: HWK-016 utilizes a stable, cleavable linker to selectively target the membrane-bound, non-shed portion of MUC16, overcoming limitations faced by earlier MUC16-targeted ADCs in tumor delivery, potentially enhancing therapeutic efficacy and improving patient survival rates.
- Biological Rationale: Real-world data presented at the SGO meeting further reinforce MUC16 as a 'super expressed' target for gynecological cancers, indicating that the development of HWK-016 aligns with current cancer treatment needs and may improve patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WHWK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WHWK
Wall Street analysts forecast WHWK stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.410
Low
7.00
Averages
7.00
High
7.00
Current: 3.410
Low
7.00
Averages
7.00
High
7.00
About WHWK
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Target Advantage: MUC16 is expressed at least two-fold higher in ovarian cancer compared to other emerging targets and is stably expressed in the most aggressive and common subtypes of endometrial cancer, indicating its potential as a clinically meaningful ADC target that could provide new treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing a Phase 1 clinical trial for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, which will provide critical clinical evidence for its application in cancer treatment.
- Technological Innovation: HWK-016 utilizes a stable, cleavable linker to selectively target the membrane-bound, non-shed portion of MUC16, overcoming limitations faced by earlier MUC16-targeted ADCs in tumor delivery, potentially enhancing therapeutic efficacy and improving patient survival rates.
- Biological Rationale: Real-world data presented at the SGO meeting further reinforce MUC16 as a 'super expressed' target for gynecological cancers, indicating that the development of HWK-016 aligns with current cancer treatment needs and may improve patient outcomes.
See More
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Expression Advantage: MUC16 exhibits expression levels in ovarian cancer that are over two-fold higher than other emerging targets, highlighting its potential as a clinically meaningful ADC target that could provide more effective treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing Phase 1 clinical trials for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, potentially introducing new therapeutic options in this area.
- Stability and Selectivity: MUC16 demonstrates high selectivity and stability across various tissue types, particularly in high-grade serous ovarian carcinoma (HGSOC), supporting its application in both early- and late-line treatments and reinforcing its rationale as a targeted therapy.
- Technological Innovation: HWK-016 utilizes a novel carbon-bridge linker technology designed to overcome the limitations of traditional ADCs by selectively targeting membrane-bound MUC16, which may significantly enhance treatment outcomes for patients.
See More
Whitehawk Presents Preclinical Findings on Next-Gen ADCs at AACR 2026
- Preclinical Research Findings: Whitehawk Therapeutics will present three preclinical research findings on antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research Annual Meeting, providing comprehensive proof-of-concept for HWK-007, HWK-016, and HWK-206 aimed at improving cancer patient outcomes.
- High Efficacy Performance: The research indicates that Whitehawk's ADCs exhibit high potency with significant tumor regressions at low single-digit mg/kg doses, and in non-human primate studies, a highest non-severely toxic dose (HNSTD) of 60 mg/kg demonstrates excellent tolerability.
- Innovative Technology Application: The study utilizes Whitehawk's proprietary
See More
Whitehawk Therapeutics Showcases Next-Gen ADCs at AACR 2026
- Preclinical Data Presentation: Whitehawk Therapeutics will present three preclinical abstracts at the 2026 American Association for Cancer Research Annual Meeting, showcasing comprehensive proof-of-concept for its ADC programs HWK-007, HWK-016, and HWK-206, aimed at improving cancer treatment outcomes.
- High Efficacy and Tolerability: These ADCs demonstrated high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, the highest non-severely toxic dose (HNSTD) reached 60 mg/kg, indicating excellent tolerability.
- Innovative Technology Utilization: Whitehawk's ADCs utilize its proprietary
See More
Whitehawk Therapeutics Reports Q4 Financial Results
- Financial Performance: Whitehawk Therapeutics reported a Q4 GAAP EPS of -$0.34, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $145.7 million, a significant increase from $47.2 million in 2024, reflecting substantial progress in financial management.
- Funding Outlook: The current cash reserves are anticipated to fund operations into 2028, providing financial security for future R&D and market expansion, thereby enhancing the company's long-term growth potential.
- Market Reaction Expectations: Despite the increase in cash reserves, the negative EPS may raise concerns about the company's future profitability, prompting investors to closely monitor subsequent strategic adjustments and financial performance.
See More
Whitehawk Therapeutics to Present at Oppenheimer 36th Annual Healthcare Conference
- Presentation Schedule: Dr. Dave Lennon, CEO of Whitehawk Therapeutics, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST, showcasing the company's latest advancements in oncology treatments.
- Webcast Availability: The presentation will be live-streamed on Whitehawk Therapeutics' investor relations website and will be available for replay for approximately 30 days post-event, ensuring that investors and the public can access key information in a timely manner.
- Company Background: Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on leveraging advanced technologies to enhance antibody-drug conjugate (ADC) cancer treatments, aiming to provide effective solutions for patients with difficult-to-treat cancers.
- Portfolio Advantages: The company boasts an advanced three-asset ADC portfolio, licensed exclusively from WuXi Biologics under a global commercialization agreement, designed to overcome the limitations of first-generation products and deliver significant therapeutic impact for patients.
See More
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Target Advantage: MUC16 is expressed at least two-fold higher in ovarian cancer compared to other emerging targets and is stably expressed in the most aggressive and common subtypes of endometrial cancer, indicating its potential as a clinically meaningful ADC target that could provide new treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing a Phase 1 clinical trial for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, which will provide critical clinical evidence for its application in cancer treatment.
- Technological Innovation: HWK-016 utilizes a stable, cleavable linker to selectively target the membrane-bound, non-shed portion of MUC16, overcoming limitations faced by earlier MUC16-targeted ADCs in tumor delivery, potentially enhancing therapeutic efficacy and improving patient survival rates.
- Biological Rationale: Real-world data presented at the SGO meeting further reinforce MUC16 as a 'super expressed' target for gynecological cancers, indicating that the development of HWK-016 aligns with current cancer treatment needs and may improve patient outcomes.
See More
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Expression Advantage: MUC16 exhibits expression levels in ovarian cancer that are over two-fold higher than other emerging targets, highlighting its potential as a clinically meaningful ADC target that could provide more effective treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing Phase 1 clinical trials for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, potentially introducing new therapeutic options in this area.
- Stability and Selectivity: MUC16 demonstrates high selectivity and stability across various tissue types, particularly in high-grade serous ovarian carcinoma (HGSOC), supporting its application in both early- and late-line treatments and reinforcing its rationale as a targeted therapy.
- Technological Innovation: HWK-016 utilizes a novel carbon-bridge linker technology designed to overcome the limitations of traditional ADCs by selectively targeting membrane-bound MUC16, which may significantly enhance treatment outcomes for patients.
See More
Whitehawk Presents Preclinical Findings on Next-Gen ADCs at AACR 2026
- Preclinical Research Findings: Whitehawk Therapeutics will present three preclinical research findings on antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research Annual Meeting, providing comprehensive proof-of-concept for HWK-007, HWK-016, and HWK-206 aimed at improving cancer patient outcomes.
- High Efficacy Performance: The research indicates that Whitehawk's ADCs exhibit high potency with significant tumor regressions at low single-digit mg/kg doses, and in non-human primate studies, a highest non-severely toxic dose (HNSTD) of 60 mg/kg demonstrates excellent tolerability.
- Innovative Technology Application: The study utilizes Whitehawk's proprietary
See More
Whitehawk Therapeutics Showcases Next-Gen ADCs at AACR 2026
- Preclinical Data Presentation: Whitehawk Therapeutics will present three preclinical abstracts at the 2026 American Association for Cancer Research Annual Meeting, showcasing comprehensive proof-of-concept for its ADC programs HWK-007, HWK-016, and HWK-206, aimed at improving cancer treatment outcomes.
- High Efficacy and Tolerability: These ADCs demonstrated high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, the highest non-severely toxic dose (HNSTD) reached 60 mg/kg, indicating excellent tolerability.
- Innovative Technology Utilization: Whitehawk's ADCs utilize its proprietary
See More
Whitehawk Therapeutics Reports Q4 Financial Results
- Financial Performance: Whitehawk Therapeutics reported a Q4 GAAP EPS of -$0.34, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $145.7 million, a significant increase from $47.2 million in 2024, reflecting substantial progress in financial management.
- Funding Outlook: The current cash reserves are anticipated to fund operations into 2028, providing financial security for future R&D and market expansion, thereby enhancing the company's long-term growth potential.
- Market Reaction Expectations: Despite the increase in cash reserves, the negative EPS may raise concerns about the company's future profitability, prompting investors to closely monitor subsequent strategic adjustments and financial performance.
See More
Whitehawk Therapeutics to Present at Oppenheimer 36th Annual Healthcare Conference
- Presentation Schedule: Dr. Dave Lennon, CEO of Whitehawk Therapeutics, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST, showcasing the company's latest advancements in oncology treatments.
- Webcast Availability: The presentation will be live-streamed on Whitehawk Therapeutics' investor relations website and will be available for replay for approximately 30 days post-event, ensuring that investors and the public can access key information in a timely manner.
- Company Background: Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on leveraging advanced technologies to enhance antibody-drug conjugate (ADC) cancer treatments, aiming to provide effective solutions for patients with difficult-to-treat cancers.
- Portfolio Advantages: The company boasts an advanced three-asset ADC portfolio, licensed exclusively from WuXi Biologics under a global commercialization agreement, designed to overcome the limitations of first-generation products and deliver significant therapeutic impact for patients.
See More
